Newsbenzinga
Stoke Therapeutics Says FDA Willing To Accept Planned Phase 3 Cognition And Behavior Analysis For Zorevunersen In Dravet Syndrome
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…